Literature DB >> 12797497

Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study.

P Buch1, J Friberg, H Scharling, P Lange, E Prescott.   

Abstract

Chronic obstructive pulmonary disease has been associated with a high frequency of arrhythmias. Few studies have analysed the role of reduced lung function in predicting atrial fibrillation (AF). The aim of the present study was to investigate the relationship between forced expiratory volume in one second (FEV1) and risk of first episode of AF in a prospective study. Data from 13,430 males and females without previous myocardial infarction, who participated in the Copenhagen City Heart Study, were analysed. New AF was assessed at re-examination after 5 yrs and by hospital admission for AF during a period of 13 yrs. Multivariate analyses were used with adjustment for cardiopulmonary risk factors. There were 62 new cases of AF at 5-yr follow-up (0.58%) and 290 cases (2.20%) diagnosed at hospitalisations. Risk of new AF at re-examination was 1.8-times higher for FEV1 between 60-80% of predicted compared with FEV1 > or = 80% after adjustment for sex, age, smoking, blood pressure, diabetes and body mass index. The risk of AF hospitalisation was 1.3-times higher for FEV1 between 60-80% and 1.8-times higher for FEV1 < 60% compared with FEV1 > or = 80%, when additional adjustment was made for education, treatment with diuretics and chest pain at activity. The authors conclude that reduced lung function is an independent predictor for incident atrial fibrillation.

Entities:  

Mesh:

Year:  2003        PMID: 12797497     DOI: 10.1183/09031936.03.00051502

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  60 in total

1.  Assessment of atrial conduction time by tissue Doppler echocardiography and P-wave dispersion in smokers.

Authors:  Erdal Akturk; Jülide Yağmur; Nusret Açıkgöz; Necip Ermiş; Mehmet Cansel; Yasin Karakuş; Hakan Taşolar; Ferhat Eyupkoca; Hasan Pekdemir
Journal:  J Interv Card Electrophysiol       Date:  2012-03-06       Impact factor: 1.900

Review 2.  [Comorbidities of COPD].

Authors:  H Watz; H Magnussen
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

3.  Ability of Reduced Lung Function to Predict Development of Atrial Fibrillation in Persons Aged 45 to 84 Years (from the Multi-Ethnic Study of Atherosclerosis-Lung Study).

Authors:  Harjit Chahal; Susan R Heckbert; R Graham Barr; David A Bluemke; Aditya Jain; Mohammadali Habibi; Alvaro Alonso; Richard Kronmal; David R Jacobs; Joao A C Lima; Karol E Watson; Kiang Liu; Lewis J Smith; Philip Greenland
Journal:  Am J Cardiol       Date:  2015-03-24       Impact factor: 2.778

Review 4.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 5.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

6.  Seasonal and Regional Variations in Chronic Obstructive Pulmonary Disease Exacerbation Rates in Adults without Cardiovascular Risk Factors.

Authors:  Jennifer Y So; Huaqing Zhao; Helen Voelker; Robert M Reed; Donald Sin; Nathaniel Marchetti; Gerard J Criner
Journal:  Ann Am Thorac Soc       Date:  2018-11

7.  B-type natriuretic peptide-guided risk assessment for postoperative complications in lung cancer surgery.

Authors:  Takashi Nojiri; Masayoshi Inoue; Yasushi Shintani; Yukiyasu Takeuchi; Hajime Maeda; Toshimitsu Hamasaki; Meinoshin Okumura
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

8.  Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease.

Authors:  Wanwarat Ananthapanyasut; Sirikarn Napan; Earl H Rudolph; Tasma Harindhanavudhi; Husam Ayash; Kelly E Guglielmi; Edgar V Lerma
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-10       Impact factor: 8.237

Review 9.  Cardiac disease in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Steven Kadiev; Gerard J Criner; Steven M Scharf; Omar A Minai; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

10.  The relationship between chronic atrial fibrillation and reduced pulmonary function in cases of preserved left ventricular systolic function.

Authors:  Hyunjae Kang; Byung Seok Bae; Jae Hoon Kim; Hee Sang Jang; Bong-Ryeol Lee; Byung-Chun Jung
Journal:  Korean Circ J       Date:  2009-09-30       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.